In their study of ovarian carcinoma, Dr. Faustman and her colleagues demonstrated that antagonistic antibodies to TNFR2 limited the expansion of TNFR2+ Tregs and inhibited their functions, with preferential activity toward Tregs of cancer patients than of control subjects [38]. Here, TNFRSF1B is linked to ovarian carcinoma.